共 50 条
- [2] One year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/Refractory mantle cell lymphomaBRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 42 - 43Wang, Michael L.Munoz, JavierGoy, AndreLocke, Frederick L.Jacobson, Caron A.Hill, Brian T.Timmerman, John M.Holmes, HoustonJaglowski, SamanthaFlinn, Ian W.McSweeney, Peter A.Miklos, David B.Pagel, John M.Kersten, Marie JoseMilpied, NoelFung, Henry C. H.Topp, Max S.Houot, RochBeitinjaneh, AmerPeng, WeiminZheng, LianqingRossi, John M.Murugappan, SwaminathanKloos, IoanaReagan, Patrick M.
- [3] Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 555 - +Wang, MichaelMunoz, JavierGoy, AndreLocke, Frederick L.Jacobson, Caron A.Hill, Brian T.Timmerman, John M.Holmes, HoustonJaglowski, SamanthaFlinn, Ian W.McSweeney, Peter A.Miklos, David B.Pagel, John M.Kersten, Marie JoseBouabdallah, KrimoKhanal, RashmiTopp, Max S.Houot, RochBeitinjaneh, AmerPeng, WeiminFang, XiangShen, Rhine R.Siddiqi, RubinaKloos, IoanaReagan, Patrick M.
- [5] Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Wang, MichaelMunoz, JavierGoy, AndreLocke, Frederick L.Jacobson, Caron AlyceHill, Brian T.Timmerman, JohnHolmes, HoustonFlinn, Ian W.Miklos, David BernardPagel, John M.Kersten, Marie JoseHouot, RochBeitinjaneh, AmerPeng, WeiminFang, XiangShen, RhineSiddiqi, RubinaKloos, IoanaReagan, Patrick Michael
- [6] Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Wang, MichaelRossi, John M.Munoz, JavierGoy, AndreLocke, Frederick LundryReagan, Patrick MichaelJacobson, Caron A.Hill, Brian T.Holmes, HoustonJaglowski, Samantha MaryPeng, WeiminZheng, LianqingFang, XiangXue, AllenRao, Arati, VBot, Adrian
- [7] Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/ Refractory Mantle Cell Lymphoma (R/R MCL)BLOOD, 2022, 140 : 9320 - 9322Munoz, JavierReagan, Patrick M.Goy, Andre H.Miklos, David B.Zheng, DanFang, XiangShen, Rhine R.Siddiqi, RubinaKloos, IoanaKersten, Marie JoseWang, Michael
- [8] ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Wang, MichaelLocke, Frederick LundryMunoz, JavierGoy, AndreHolmes, Houston EcclestonSiddiqi, TanyaFlinn, IanMcSweeney, Peter A.Reagan, Patrick MichaelHill, Brian ThomasJacobson, Caron A.Rizzieri, David A.Heffner, Leonard T.Jaglowski, Samantha MaryMiklos, David BernardShaughnessy, PaulUnabia, SherryRossi, John M.Jiang, YizhouJain, Rajul K.
- [9] Pharmacological profile and clinical outcomes of KTE-X19 by prior bruton tyrosine kinase inhibitor exposure or mantle cell lymphoma morphology in patients with relapsed/refractory mantle cell lymphoma in the ZUMA-2 trialBRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 43 - 44Wang, MichaelRossi, John M.Munoz, JavierGoy, AndreLocke, Frederick L.Reagan, Patrick M.Jacobson, Caron A.Hill, Brian T.Holmes, HoustonJaglowski, SamanthaPeng, WeiminZheng, LianqingFang, XiangXue, AllenKloos, IoanaBot, Adrian